# A pilot study on the effect of niacin on pulmonary arterial pressure

Submission date 27/03/2015	<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li><li>Protocol</li></ul>
Registration date 23/04/2015	<b>Overall study status</b> Completed	<ul> <li>[] Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 17/05/2023	<b>Condition category</b> Circulatory System	<ul> <li>Individual participant data</li> </ul>

## Plain English summary of protocol

Background and study aims

The aim of this study is to determine whether the drug niacin can help patients with high blood pressure in their lung arteries, also called pulmonary hypertension. This is a study specifically for volunteers who do NOT have high blood pressure in the lung's arteries. This study is important because the medications that are used to treat pulmonary arterial hypertension are very limited. Any new medications that might work to lower pulmonary arterial blood pressure would be very helpful for these patients.

Who can participate?

Patients aged over 18 with a tricuspid regurgitation jet velocity over 2.7 m/s on an inpatient echocardiogram during their current hospital stay.

## What does the study involve?

First, you will get an echocardiogram, which is a non-invasive test that uses ultrasound waves to evaluate a picture of the heart. You will then be randomly allocated to take one of three different pills: niacin 100 mg pill, niacin 500 mg pill, or a sugar pill (a placebo). Neither you nor the investigator will know what group you in. One hour after taking your pill, you will get a second ultrasound of your heart.

What are the possible benefits and risks of participating?

We do not expect for you to have any direct medical benefits from participating in this study, but we hope that the information we gain will help patients with pulmonary arterial hypertension. You will be compensated with a \$20 gift card for your participation. This study will not interfere with the evaluation and treatment of the condition that brought you to the hospital. It will not add any cost to your stay and will not delay your discharge. Risks and side effects related to the study include flushing of your skin after taking niacin. There may also be side effects that we cannot predict. Other drugs will be given to make side effects that occur less serious and less uncomfortable.

Where is the study run from? MedStar Georgetown University Hospital (USA). When is the study starting and how long is it expected to run for? March 2013 to April 2014.

Who is funding the study? Folger Grant for Cardiovascular Prevention.

Who is the main contact? Martin McNamara

# **Contact information**

**Type(s)** Public

**Contact name** Mr Martin McNamara

ORCID ID http://orcid.org/0000-0002-4849-3313

**Contact details** 17612 Charity Lane Germantown United States of America 20874

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers IIS12067

# Study information

## Scientific Title

A pilot randomized double-blinded single-dose provocation study on the effect of niacin on pulmonary arterial pressure

## Study objectives

We hypothesized that immediate-release niacin would reduce right ventricular systolic pressure in patients with pulmonary hypertension via the release of vasodilating prostaglandins in a randomized, double-blinded, single-dose provocation study.

## Ethics approval required

Old ethics approval format

### Ethics approval(s)

Institutional Review Board (IRB) of Georgetown University Hospital, 10/05/2011, study number 2012-067

**Study design** Randomized double-blinded single-dose provocation study

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Hospital

**Study type(s)** Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Pulmonary hypertension

### Interventions

Subjects were randomized in a 1:2:2 ratio to receive a single dose of either placebo, niacin 100 mg or niacin 500 mg, respectively. TR jet velocities were measured immediately before, and one-hour post dose, corresponding to peak niacin absorption and prostaglandin release.

Intervention Type

Drug

**Phase** Not Applicable

Drug/device/biological/vaccine name(s) Niacin

## Primary outcome measure

Change in mean tricuspid regurgitation jet velocity measured in meters/second one hour after study drug administration.

## Secondary outcome measures

Change in maximum tricuspid regurgitation jet velocity measured in meters/second one hour after study drug administration.

## Overall study start date

07/06/2012

**Completion date** 

12/06/2014

# Eligibility

## Key inclusion criteria

1. Over the age of 18 2. Display a tricuspid regurgitation jet velocity over 2.7 m/s on an inpatient echocardiogram during their current hospital stay

## Participant type(s)

Patient

**Age group** Adult

**Lower age limit** 18 Years

Sex Both

Target number of participants

50

**Total final enrolment** 49

## Key exclusion criteria

1. Inability to provide written informed consent

2. Known pulmonary vascular disease

3. Known intolerance to niacin or current treatment with niacin

4. Current treatment with a non-steroidal anti-inflammatory drug (NSAID)

5. Known liver disease (AST/ALT > 3x the upper limit of normal)

6. Patients currently on ventilator support or using a bi-level positive airway pressure (BiPAP) device

## Date of first enrolment

25/03/2013

# Date of final enrolment

14/04/2014

# Locations

# Countries of recruitment

United States of America

Study participating centre

# Sponsor information

**Organisation** Georgetown University Institutional Review Board

**Sponsor details** 37th and O street Washington, D.C. United States of America 20057

**Sponsor type** University/education

ROR https://ror.org/05vzafd60

# Funder(s)

**Funder type** Other

**Funder Name** Folger Grant for Cardiovascular Prevention

# **Results and Publications**

**Publication and dissemination plan** We hope to publish our results as soon as possible.

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Available on request

Study outputs						
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?	
Results article	results	21/11/2015		Yes	No	